Proteomics data of ovine mastitis associated with Mannheimia haemolytica.

Proteomics data have been obtained from experimental mastitis in ewes after intramammary challenge with Mannheimia haemolytica. Animals were sampled before and sequentially after challenge; blood plasma and milk whey samples were produced and were subjected to proteomics evaluation by means of two-dimensional gel electrophoresis and MALDI-TOF mass spectrometry. Full protein maps and differential proteomics in sequential samples from blood plasma and milk whey of experimental ewes were presented. Post-challenge, 33 and 89 proteins were identified with differential abundance in blood plasma and milk whey, respectively. Also, 74 proteins were identified with differential abundance between the inoculated and contralateral glands. The data provide further insight in the pathogenesis of mastitis in sheep and indicate potential biomarkers for the disease. The data are further discussed in the research article "Differential quantitative proteomics study of experimental Mannheimia haemolytica mastitis in sheep" [1].

Differential quantitative proteomics study of experimental Mannheimia haemolytica mastitis in sheep.

Objective was the differential quantitative proteomics study of ovine mastitis induced by Mannheimia haemolytica; clinical, microbiological, cytological and histopathological methods were employed for confirmation and monitoring. Proteins were separated by two-dimensional gel electrophoresis (2-DE) for all samples and differentially abundant proteins were identified by mass spectrometry; comparisons were performed with pre- (blood, milk) and post- (milk of contralateral gland) inoculation findings. Animals developed mastitis, confirmed by isolation of challenge strain and increase of neutrophils in milk and by histopathological evidence. In blood plasma, 33 differentially abundant proteins (compared to findings before challenge) were identified: 6 with decrease, 13 with new appearance and 14 with varying abundance. In a post-challenge milk whey protein reference map, 65 proteins were identified; actin cytoplasmic-1, beta-lactoglobulin-1/B, cathelicidin-1 predominated. Further, 89 differentially abundant proteins (compared to findings before challenge) were identified: 18 with decrease, 53 with new appearance, 3 with increase and 15 with varying abundance; 15 proteins showed status changes in blood plasma and milk whey. Differential abundance from inoculated and contralateral glands revealed 74 proteins only from the inoculated gland. Most differentially abundant proteins in milk whey were involved in cell organisation and biogenesis (n = 17) or in inflammatory and defence response (n = 13). SIGNIFICANCE: The proteomes of blood and milk from ewes with experimental mastitis caused by Mannheimia haemolytica and the differential proteomics in sequential samples after challenge are presented for the first time. This is the first detailed proteomics study in M. haemolytica-associated mastitis in ewes. An experimental model fully simulating natural mastitis has been used. Use of experimentally induced mastitis minimised potential variations and allowed consistency of results. The study included evaluation of changes in blood plasma and milk whey. Protein patterns have been studied, indicating with great accuracy changes that had occurred as part of the disease process and development, during the acute phase of infection. Relevant protein-protein interactions were studied. The entirety of proteomics findings has suggested that affected ewes had mounted a defence response that had been regulated by many proteins (e.g., cathelicidins, haptoglobin, serum amyloid A) and through various pathways (e.g., acute phase response, binding and transporting significant ions and molecules); these were interdependent at various points. Potential biomarkers have been indicated for use in diagnostic assays of mastitis.

Combined treatment of eCG and a non-selective inhibitor of phosphodiesterases for enhancing reproductive performance in ewes

The aim of this study was to evaluate the effect of the non-selective phosphodiesterase inhibitor 3- isobutyl-1-methyl-xanthine (IBMX) given concomitantly with eCG on reproductive performance of ewes. In trial 1, eighty ewes were allocated into 8 groups (AC, A1, A2, A3 and DC, D1, D2, D3). Oestruses were synchronized by progestagen sponges. At sponges removal all ewes of A groups received 400 IU of eCG. Concomitantly with eCG, ewes of groups A1, A2 or A3 received IMBX at the dose of 2.5, 5.0 or 25.0 mg, respectively. Ewes of D1, D2 or D3 groups received only IBMX at the same doses, respectively; in each case, ewes of AC or DC groups were controls (C). In trial 2, one hundred eighteen ewes were allocated into 4 groups (BC1, B1 and BC2, B2). Oestruses were synchronized by progestagen sponges. At sponges removal ewes of BC1 or B1 received 200 IU of eCG, while ewes of BC2 or B2 groups received 100 IU. At the same time only ewes of B1 or B2 groups received 2.5 mg IBMX. In both trials, 48 hours after hormonal treatment, ewes were mated. In trial 1, pregnancy or lambing rate did not differ among A or D groups (P > 0.05). Total lambs per ewe were significantly higher in A1 compared to AC, A2, A3 or D1 groups (P 0.05). In trial 2, pregnancy or lambing rate did not differ among B groups (P > 0.05). Total lambs per ewe were significantly higher (P < 0.05) in B1 and B2 compared to BC1 and BC2 groups, respectively. These results indicate that IBMX combined with eCG at the end of an oestrus synchronization treatment improves litter size probably by increasing ovulation rate in ewes. This latter effect seems to be mainly dependent on the amount of gonadotrophins used.

Combined treatment of eCG and a non-selective inhibitor of phosphodiesterases for enhancing reproductive performance in ewes

The aim of this study was to evaluate the effect of the non-selective phosphodiesterase inhibitor 3- isobutyl-1-methyl-xanthine (IBMX) given concomitantly with eCG on reproductive performance of ewes. In trial 1, eighty ewes were allocated into 8 groups (AC, A1, A2, A3 and DC, D1, D2, D3). Oestruses were synchronized by progestagen sponges. At sponges removal all ewes of A groups received 400 IU of eCG. Concomitantly with eCG, ewes of groups A1, A2 or A3 received IMBX at the dose of 2.5, 5.0 or 25.0 mg, respectively. Ewes of D1, D2 or D3 groups received only IBMX at the same doses, respectively; in each case, ewes of AC or DC groups were controls (C). In trial 2, one hundred eighteen ewes were allocated into 4 groups (BC1, B1 and BC2, B2). Oestruses were synchronized by progestagen sponges. At sponges removal ewes of BC1 or B1 received 200 IU of eCG, while ewes of BC2 or B2 groups received 100 IU. At the same time only ewes of B1 or B2 groups received 2.5 mg IBMX. In both trials, 48 hours after hormonal treatment, ewes were mated. In trial 1, pregnancy or lambing rate did not differ among A or D groups (P > 0.05). Total lambs per ewe were significantly higher in A1 compared to AC, A2, A3 or D1 groups (P < 0.05), but did not differ among D groups (P > 0.05). In trial 2, pregnancy or lambing rate did not differ among B groups (P > 0.05). Total lambs per ewe were significantly higher (P < 0.05) in B1 and B2 compared to BC1 and BC2 groups, respectively. These results indicate that IBMX combined with eCG at the end of an oestrus synchronization treatment improves litter size probably by increasing ovulation rate in ewes. This latter effect seems to be mainly dependent on the amount of gonadotrophins used.(AU)